MYC and neoplasm: In conclusion, using an in vitro model of hypoxia, susceptible to mimic more closely the in vivo hypoxic tumor conditions, we depicted metabolomic profiles of response to the combination of rapamycin plus irinotecan, determined by a balance between upstream signals in MYC and mTOR/HIF-1/2α pathways.